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• 5α-reductase (5AR) inhibitors have antiandrogen effects, and have been shown to 
decrease cancer cell proliferation and metastasis. 
• We conducted a nested case-control study within the Scottish Primary Care Clinical 
Information Unit Research database to assess the association between 5AR inhibitor 
use and gastro-oesophageal cancer. 
• There was some evidence of reduced gastro-oesophageal cancer risk among 5AR 
inhibitor users, particularly for finasteride. 
• Larger epidemiological studies are required before randomised controlled trials are 
considered. 
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Purpose: The strong male predominance of gastro-oesophageal cancer suggests sex 
hormones play an important role. 5α-reductase (5AR) inhibitors have antiandrogen effects, 
and have been shown to decrease cancer cell proliferation and metastasis. We conducted the 
first epidemiologic investigation into the association between 5AR inhibitor use and gastro-
oesophageal cancer risk. 
 
Methods:  We conducted a nested case-control study within the Scottish Primary Care Clinical 
Information Unit Research database. Male cases diagnosed with oesophageal or gastric 
cancer between 1999 and 2011 were matched to up to five male controls based on birth year, 
diagnosis year and general practice. We used electronic prescribing records to ascertain 
medication use. We used conditional logistic regression to calculate odds ratios (ORs) for the 
association between 5AR inhibitor use and cancer risk, after adjusting for comorbidities and 
aspirin, statin or proton pump inhibitor use.  
 
Results: The study included 2,003 gastro-oesophageal cancer cases and 9,650 controls. There 
was some evidence of reduced gastro-oesophageal cancer risk among 5AR inhibitor users 
(adjusted OR=0.75; 95% CI: 0.56, 1.02), particularly for finasteride (adjusted OR=0.68; 95% CI 
0.50, 0.94). These decreases were more marked among those who received at least 3 years 
of 5AR inhibitors (adjusted OR= 0.54; 95% CI: 0.27, 1.05; p-value=0.071) or finasteride 




Conclusions: We found evidence of reduced gastro-oesophageal cancer risk among users of 
5AR inhibitors, particularly finasteride. However, larger epidemiological studies are required 





Oesophageal and gastric cancer are among the most common cancers in the world, with 
around 456,000 and 952,000 new cases diagnosed annually.(1) Prognosis is extremely poor, 
even in high-income countries such as the UK, where nearly 55% of patients die within one 
year of diagnosis.(2)  The strong male predominance of gastro-oesophageal cancer(3-5) has 
prompted much interest in the role of sex hormones.(6, 7) This hormonal hypothesis is 
supported by findings of reduced gastric cancer incidence among hormone replacement 
therapy users, and women with a longer time between menarche and menopause.(8) 
 
5α-reductase (5AR) inhibitors (including finasteride and dutasteride) are widely used(9) 
medications for the treatment of benign prostatic hyperplasia(10), the most common urologic 
disease among elderly males causing symptoms including nocturia urinary urgency.(11) Once 
prescribed, they are used indefinitely to reduce prostate size by inhibiting the androgen 
receptor thus preventing the conversion of testosterone to the more biologically active 
dihydrotestosterone.(12, 13) 5AR inhibitors have been shown to increase the ratio of 
oestrogen to testosterone(14), and have been linked with some hormonal side effects such 
as gynaecomastia.(15) Preclinical evidence that androgen receptors are present within 
oesophageal (16-18) and gastric cancer tumours (19-21), and that their inhibition reduces cell 
proliferation and migration(22, 23), suggests that medications with hormonal effects could 
influence gastro-oesophageal cancer risk. Surprisingly, clinical studies have yet to assess the 




Consequently, in a population-based primary care cohort from Scotland, we conducted the 






We conducted a nested case-control study within the Primary Care Clinical Information Unit 
Research (PCCIUR) database.(24) Between 1993 and 2011, the PCCIUR collected 
computerised medical records from approximately 15% of the Scottish general practice 
population, and includes details on patient demographics (e.g. age, gender), primary care 
encounters, clinical diagnoses and prescriptions. Access to the PCCIUR data was approved by 
the Research Applications and Data Management Team, University of Aberdeen. Ethical 
approval for this study was supplied by the Queen’s University Belfast, School of Medicine 
Ethics Committee (reference number: 15.43). 
 
Cases and controls 
Our primary outcome was gastro-oesophageal cancer since classifying tumours arising close 
to the oesophagogastric junction is difficult.(25, 26) Cases and controls were restricted to 
males as 5AR inhibitors are not used in females. Cases were defined as patients with a primary 
oesophageal (Read code: B10..) or gastric (Read code: B11..) cancer diagnosis between 1st 
January 1999 and 30th April 2011. Up to five controls were randomly selected for each case 
matched on year of birth   and general practice (equivalent to US family practice centres). 
Controls were chosen to ensure they were registered with the general practice during the 
year of the cases cancer diagnosis to prevent confounding due to secular time effects or 
changes in coding practices. The index date was defined as the diagnosis date of the case in 




Definition of exposure 
We identified 5AR inhibitor use from electronic prescription records. We used the British 
National Formulary to compile a list of proprietary and generic names for 5AR inhibitor 
medications (Appendix 1). The start of the exposure assessment window was the latest of 1st 
January 1996 (as prescriptions before this were less likely to be generated electronically) or 
the date of general practice registration. The exposure assessment window ended one year 
before cancer diagnosis to prevent reverse causation.  Additionally, the exposure assessment 
window was truncated to ensure it was identical across the matched groups.(27) Cases and 
controls with an earlier cancer diagnosis (other than non-melanoma skin cancer), and those 
with less than a three year exposure assessment window, were excluded from the study. We 
defined patients as users if they had at least one prescription during the exposure  assessment 
window.  
 
To enable the testing of dose‐response relationships, we extracted data on the medication 
prescribed, number of packs/tablets and medication strength, and calculated defined daily 
doses (DDDs). The DDD system is a validated measure of drug consumption maintained by 
the World Health Organization.(28) A single DDD is the average maintenance dose per day of 
a drug used for its main indication in adults (e.g. BPH for finasteride). We calculated the total 
number of DDDs received during the exposure window and categorized patients into those 
receiving 0 (never users), between 1 and 365 DDDs (less than 1 years usage), between 366 






We identified eleven comorbidities (myocardial infarction, heart failure, peripheral vascular 
disease, cerebrovascular disease, connective tissue disease, dementia, chronic obstructive 
pulmonary disease, rheumatoid arthritis, diabetes, renal disease, liver disease) using Read 
codes recorded by the GP during the exposure  assessment window.(29) This list was based 
on the comorbidities comprising the Charlson comorbidity index after removing rare diseases 
within the UK (e.g. AIDS), cancer (as those with previous cancer are excluded from the study), 
and those which may lie on the causal pathway between 5ARI use and gastro-oesophageal 
cancer (e.g. peptic ulcer). Read codes are a thesaurus of clinical terms broadly based on ICD codes 
and have been widely used within UK general practice since 1985.(30)  
 
Use of aspirin, statins, and proton pump inhibitors within the exposure assessment window 
was identified from prescription records (Appendix 1), as associations with oesophageal 
and/or gastric cancer have been identified previously.(31-34) Lifestyle data including obesity 
(body mass index, BMI>30), smoking status (never, ex, current) and alcohol use (none, low 
[e.g. moderate or light drinker], high [e.g. above recommended limits, chronic alcoholism]) 
were also recorded in the PCCIUR data using Read codes. Lifestyle factors were assessed using 
the record closest to the date of cases cancer diagnosis within the exposure assessment window.  
 
Statistical analysis 
We calculated descriptive statistics, and compared the demographics and clinical 
characteristics of the cases and controls. We used conditional logistic regression to estimate 
odds ratios (ORs) with 95% confidence intervals (CIs) for the association between 5AR 
inhibitor use and gastro-oesophageal cancer risk.  The matched design accounted for the 
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effect of age, general practice and year of diagnosis with additional adjustments made for 
statin use (yes/no), aspirin use (yes/no), proton pump inhibitor use (yes/no), and the 
presence of each comorbidity (yes/no) using regression. We conducted separate site-specific 
analysis for oesophageal and gastric cancer, and used an interaction test to formally test for 
differences across sites. Similarly, we conducted separate gastro-oesophageal analyses for 
finasteride and dutasteride, as they use different mechanisms to inhibit testosterone 
metabolism.(35) 
 
Sensitivity and subgroup analyses 
We investigated the impact of additionally adjusting for lifestyle factors (smoking, alcohol 
consumption and obesity) using complete case and multiple imputation with chained 
equations methods. The imputation used ordered logit models with age and deprivation 
(Scottish Index of Multiple Deprivation quintile based on the postcode of the GP practice), separately 
for cases and controls. Briefly, this is a simulation-based approach for handling missing data 
which leads to valid statistical inferences.(36) Sensitivity analyses were also conducted 
investigating the impact of excluding prescriptions in the two years prior to the index date (as 
opposed to one in the main analysis), and defining medication users as patients with at least 
three 5AR inhibitor prescriptions (as opposed to one in the main analysis).  
 
Finally, to investigate confounding, we conducted separate negative control analyses(37) for 
liver (Read code: B15..) and pancreatic (Read code: B17..) cancer, as there is little evidence of 
androgen receptor expression in these sites(38, 39), but they should be subject to many of 
the same potential biases as gastro-oesophageal cancer. Therefore, if confounding was 
driving our gastro-oesophageal cancer results we would expect to see similar associations for 
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liver and pancreatic cancer. Conversely, findings of meaningful associations for gastro-
oesophageal cancer, which are not replicated among the negative controls, would support a 





We identified 2,003 cases of gastro-oesophageal cancer (1,364 oesophageal and 639 gastric 
cancer) (Table 1). An average of 4.8 controls were matched for each case, with a median 
exposure assessment window of 5.4 years (min 3.0, max 15.1).  A larger proportion of cases 
than controls had a history of COPD (12.3 vs. 8.6%), and were more likely to be current or ex-
smokers (70.8 vs. 61.0%), drink high levels of alcohol (9.7 vs. 7.3%) and have a BMI under 
thirty (85.7 vs. 80.1%). 
 
Association between 5AR inhibitor use and gastro-oesophageal cancer 
Overall, 2.7% of cases and 3.2% of controls used 5AR inhibitors. Finasteride (2.9% of study 
population) was more commonly used than dutasteride (0.3%). There was some evidence of 
a reduction in gastro-oesophageal cancer risk among 5AR inhibitor users (ORadj= 0.75; 95% CI: 
0.56, 1.02; Table 2), particularly those using finasteride (ORadj= 0.68; 95% CI: 0.50, 0.94).  In 
contrast, there was no significant association between dutasteride use and gastro-
oesophageal cancer risk (ORadj= 1.53; 95% CI 0.67, 3.50). There were more marked 
associations among patients who received at least 3 years of 5AR inhibitors (adjusted OR= 
0.54; 95% CI: 0.27, 1.05; p-value=0.071) or finasteride (adjusted OR=0.49; 95% CI 0.24, 0.99; 
p-value=0.046). There was no evidence of a difference in associations between gastric (ORadj= 
0.68; 95% CI: 0.39, 1.17) or oesophageal (ORadj= 0.78; 95% CI: 0.55, 1.13) cancer (p-value for 




Sensitivity and subgroup analysis 
In general, our results were little altered in sensitivity analyses (Table 3).  Similar findings were 
observed when excluding prescriptions in the two years prior to diagnosis, or when the 
exposure definition of ‘ever use’ was based upon three or more prescriptions. Additionally 
adjusting for lifestyle factors (smoking, alcohol consumption, and obesity) using multiple 
imputation methods resulted in similar findings to the main analysis. Our estimates were 
slightly attenuated when adjusting for lifestyle factors using complete-case methods, 
although our conclusions were unaltered. Finally, in negative control analyses, there was no 
evidence of a protective association between 5AR inhibitor use and liver (ORadj= 1.03; 95% CI: 




Summary of main findings 
In this novel population-based study of gastro-oesophageal cancer cases and controls, there 
was evidence that users of 5AR inhibitors, and particularly finasteride, had lower cancer risk 
than non-users.  These associations were most marked in those receiving at least 3 years of 
5AR inhibitors, and were not replicated in negative control analyses for liver or pancreatic 
cancer. 
 
Strengths and limitations 
Our study is the first to investigate the effect of 5AR inhibitor use on gastro-oesophageal 
cancer risk.  It is based on high-quality and nationally representative data.(41) We used 
prescribing information collected as part of routine clinical care, in many cases, several years 
before the onset of oesophageal or gastric cancer, which accurately reflects GP prescribing 
practices and negates the risk of recall bias.  Although a weakness of this approach is that we 
do not know if patients used their medications, the main conclusions were similar when 
restricting our analysis to those who received multiple repeat 5AR inhibitor prescriptions 
(>12), where non-compliance is likely to be less of a concern.  
 
Our study is observational and hence open to confounding. Although we have controlled for 
several of the key determinants of cancer risk through the matched design and analysis (e.g. 
age, comorbidities), some other risk factors, including ethnicity and nutrition, were not 
available. However, the lack of a protective association for pancreatic and liver cancer, which 
should share many of the same potential biases as gastro-oesophageal cancer, suggests that 
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residual confounding is not solely driving our results. As almost all patients received 5ARI 
inhibitors for BPH we were unable to adjust for this factor in our analysis. Although this could 
have introduced confounding by indication in our analysis, we think this is unlikely given the 
lack of any evidence of an association between BPH and gastro-oesophageal cancer risk.  The 
statistical power of our analysis is limited by our sample size and the relatively low use of 5AR 
inhibitors within our study population.   
   
Our analysis is based on cancer diagnoses recorded in GP electronic records.  Although a 
recent Clinical Practice Research Datalink study found that over 95% of gastro-oesophageal 
cancers are captured within GP records(42), a higher proportion of oesophageal cancers were 
recorded the PCCIUR data than in the Scottish Cancer Registry, which could suggest some 
misclassification of cancer site in our study.(43) This potential issue would not affect our 
primary analysis which combined oesophageal and gastric cancers. Finally, histological data 
were not available to allow a separate analysis of squamous cell carcinoma and 
adenocarcinoma, the two most common forms of gastro-oesophageal cancer. One preclinical 
study has demonstrated a higher concentration of androgen receptors in adenocarcinoma 
compared to squamous cell carcinoma, suggesting that 5AR inhibitors may have stronger 
effects in adenocarcinoma tumours.(44) Our exposure data is based on prescription data so 
we can not be sure that patients consumed their medications. We would expect the 
magnitude of this potential misclassification to be small and to result in slightly attenuated 




Comparisons with other research 
To our knowledge, this is the first study to investigate the association between 5AR inhibitors 
and gastro-oesophageal cancer risk. Several studies have previously demonstrated lower 
prostate cancer risk among 5AR inhibitor users.(45-49) For example, one randomised 
controlled trial reported that patients treated with finasteride had a 30% (95% CI: 24, 35) 
lower risk of prostate cancer than those assigned to a placebo.(47) Epidemiological studies 
have also reported a reduced risk of bladder cancer, but not breast cancer, among 5AR 
inhibitor users.(50-52) 
 
Implications for clinicians, policymakers and researchers 
Our results suggest that the use of 5AR inhibitors may be associated with reduced gastro-
oesophageal cancer risk. These results are compatible with preclinical evidence from 
oesophageal and gastric cancer cell lines demonstrating that androgen receptor inhibition 
leads to decreased proliferation and metastasis (22, 23), and are consistent with ecological 
findings of lower gastro-oesophageal cancer incidence among females(3) and prostate cancer 
survivors (who would have typically been treated with anti-androgen therapy).(53) Our 
finding of a weaker association for dutasteride is difficult to explain as it is a stronger 
androgen receptor inhibitor, and has a longer half-life than finasteride.(35) However, it is 
possible that our inconsistent findings reflect the very low use of dutasteride within our study 
population (<0.3%), which hindered our statistical power. Differences in gastro-oesophageal 
cancer risk by 5AR inhibitor type should be explored further in larger studies and/or in settings 




The role of 5AR inhibitors as a chemopreventive agent should be explored further, particularly 
as they are inexpensive (finasteride costs £1.73 [$2.24] per 28-tablet pack)(54), have no major 
safety concerns, and are well tolerated by patients.(55, 56) These medications may have 
greatest utility among patients at high risk of gastro-oesophageal cancer, such as those with 
Barrett’s oesophagus or advanced gastric premalignant lesions.(57, 58) In this paper we have 
demonstrated that the association with gastro-oesophageal cancer adheres to several of Hill's 
criteria for causation including biological plausibility, experimental evidence, strength of 
association, temporality, biological gradient, and specificity.(59) However, our findings should 
be replicated in larger epidemiological studies, with detailed information on tumour 




In this novel population-based study, we found a 25% lower gastro-oesophageal cancer risk 
among 5AR inhibitor users. This association should be replicated in larger epidemiological 
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Tables and Figures 
Table 1: Characteristics of controls and cases with gastro-oesophageal cancer 
 Cases (%) Controls (%) 
Count 2,003 9,650 
Median Exposure Years (IQR) 5.4 (4.0,7.6) 5.4 (4.0,7.6) 
Year of Diagnosis   
1999-2003 670 (33.4) 3,238 (33.6) 
2004-2007 921 (46.0) 4,416 (45.8) 
2008-2011 412 (20.6) 1,996 (20.7) 
Mean Age (SD) 68.2 (11.0) 67.7 (10.8) 
<39 18 (0.9) 89 (0.9) 
40-59 421 (21.0) 2,093 (21.7) 
60-79 1,264 (63.1) 6,193 (64.2) 
80+ 300 (15.0) 1,275 (13.2) 
Smoking status   
Non-smoker 498 (29.2) 2,871 (39.0) 
Ex-smoker 649 (38.0) 2,655 (36.1) 
Current smoker 561 (32.8) 1,835 (24.9) 
Missing 295 2,289 
Alcohol Consumption   
No 259 (17.6) 1,123 (17.4) 
Low 1,071 (72.7) 4,857 (75.3) 
High 143 (9.7) 474 (7.3) 
Missing 530 3,196 
Obesity   
Not Obese 1,716 (85.7) 7,725 (80.1) 
Obese 287 (14.3) 1,925 (19.9) 
Deprivation Quintile   
1 (Least Deprived) 235 (11.9) 1,113 (11.7) 
2 358 (18.1) 1,713 (18.0) 
3 431 (21.8) 2,092 (22.0) 
4 476 (24.1) 2,319 (24.4) 
5 (Most Deprived) 473 (24.0) 2,271 (23.9) 
Missing 30 142 
Common Comorbiditiesa    
Connective Tissue Disease 853 (42.6) 4,145 (43.0) 
Diabetes 229 (11.4) 1,019 (10.6) 
MI 216 (10.8) 936 (9.7) 
COPD 246 (12.3) 830 (8.6) 
CVD 199 (9.9) 785 (8.1) 
Other Medication Use   
Aspirin 611 (30.5) 2,802 (29.0) 
Statin 507 (25.3) 2,316 (24.0) 
Proton pump inhibitors 521 (26.0) 1,910 (19.8) 
   
                                                          
a For brevity, only the 5 most common comorbidities are listed. The full analysis included myocardial infarction 
(MI), heart failure, peripheral vascular disease, cerebrovascular disease (CVD), connective tissue disease, 

















Any 5AR inhibitor     
Never use    1,949 (97.3)    9,343 (96.8) Ref Ref  
Ever use       54 (2.7)      307 (3.2) 0.80 (0.59,1.08) 0.75 (0.56,1.02) 0.065 
<365 DDDs       22 (1.1%)      127 (1.3%) 0.77 (0.49,1.22) 0.74 (0.47,1.17) 0.201 
366 - 1095 DDDs       22 (1.1%)      100 (1.0%) 1.03 (0.64,1.65) 0.94 (0.58,1.53) 0.813 
>1095 DDDs       10 (0.5%)       80 (0.8%) 0.57 (0.29,1.10) 0.54 (0.27,1.05) 0.071 
Finasteride  
  Never use    1,956 (97.7)    9,357 (97.0) Ref Ref  
  Ever use       47 (2.3)      293 (3.0) 0.73 (0.53,1.00) 0.68 (0.50,0.94) 0.020 
<365 DDDs       18 (0.9%)      119 (1.2%) 0.69 (0.42,1.13) 0.65 (0.39,1.07) 0.090 
366 - 1095 DDDs       20 (1.0%)       95 (1.0%) 0.98 (0.60,1.61) 0.90 (0.54,1.48) 0.667 
>1095 DDDs        9 (0.4%)       79 (0.8%) 0.51 (0.25,1.03) 0.49 (0.24,0.99) 0.046 
Dutasteride      
  Never use    1,995 (99.6)    9,627 (99.8) Ref Ref  
  Ever use        8 (0.4)       23 (0.2) 1.53 (0.67,3.48) 1.53 (0.67,3.50) 0.312 
  <365 DDDs        6 (0.3%)       18 (0.2%) 1.41 (0.55,3.61) 1.45 (0.56,3.73) 0.439 
366 - 1095 DDDs        1 (0.0%)        4 (0.0%) 1.21 (0.12,12.06) 1.16 (0.12,11.65) 0.899 
>1095 DDDs        1 (0.0%)        1 (0.0%) 5.00 (0.31,79.94) 4.03 (0.25,65.80) 0.328 
Oesophageal 
Any 5AR inhibitor      
Never use    1,326 (97.2)    6,366 (96.9) Ref Ref  
Ever use       38 (2.8)      202 (3.1) 0.85 (0.59,1.21) 0.78 (0.55,1.13) 0.191 
    <365 DDDs       14 (1.0%)       86 (1.3%) 0.71 (0.40,1.26) 0.67 (0.38,1.20) 0.178 
    366 - 1095 DDDs       15 (1.1%)       64 (1.0%) 1.09 (0.61,1.95) 1.00 (0.55,1.80) 0.990 
    >1095 DDDs        9 (0.7%)       52 (0.8%) 0.79 (0.38,1.63) 0.72 (0.35,1.51) 0.387 
Gastric 
Any 5AR inhibitor      
Never use      623 (97.5)    2,977 (96.6) Ref Ref  
Ever use       16 (2.5)      105 (3.4) 0.71 (0.42,1.21) 0.68 (0.39,1.17) 0.162 
<365 DDDs        8 (1.3%)       41 (1.3%) 0.91 (0.43,1.95) 0.86 (0.40,1.86) 0.701 
366 - 1095 DDDs        7 (1.1%)       36 (1.2%) 0.93 (0.41,2.11) 0.87 (0.38,2.00) 0.745 
>1095 DDDs        1 (0.2%)       28 (0.9%) 0.16 (0.02,1.18) 0.16 (0.02,1.20) 0.075 
                                                          
b OR: odds ratio; CI: confidence interval 
c Conditioned on year of birth, general practice and year of diagnosis 
d Additionally adjusted for use of aspirin, statins and proton pump inhibitors, and the presence of myocardial 
infarction, heart failure, peripheral vascular disease, cerebrovascular disease, connective tissue disease, 
dementia, chronic obstructive pulmonary disease, rheumatoid arthritis, diabetes, renal disease and liver disease.  
24 
 







Adjusted OR  
(95% CI) g 
Gastro-oesophageal 
2- year exposure lag     
Never use 1,964 (98.1) 9,404 (97.5) Ref Ref 
Ever use 39 (1.9) 246 (2.5) 0.73 (0.52,1.04) 0.68 (0.48,0.97) 
Ever use ≥3 prescriptions     
Never use 1,955 (97.6) 9,384 (97.2) Ref Ref 
Ever use 48 (2.4) 266 (2.8) 0.82 (0.59,1.12) 0.77 (0.56,1.07) 
MI lifestyle adjustedh     
Never use 1,949 (97.3) 9,343 (96.8) Ref Ref 
Ever use 54 (2.7) 307 (3.2) 0.80 (0.59,1.08) 0.78 (0.58,1.06) 
Lifestyle complete casei     
Never use 1,396 (96.8) 5,927 (96.2) Ref Ref 
Ever use 46 (3.2) 234 (3.8) 0.85 (0.61,1.19) 0.86 (0.61,1.21) 
Liver 
Any 5AR inhibitor     
Never use      289 (96.0)    1,410 (96.5) Ref Ref 
Ever use       12 (4.0)       51 (3.5) 1.17 (0.60,2.26) 1.03 (0.50,2.11) 
Pancreatic 
Any 5AR inhibitor     
Never use      396 (96.4)    1,914 (96.4) Ref Ref 
Ever use       15 (3.6)       72 (3.6) 0.97 (0.54,1.74) 0.91 (0.50,1.69) 
                                                          
e OR: odds ratio; CI: confidence interval 
f Conditioned on year of birth, general practice and year of diagnosis 
g Additionally adjusted for use of aspirin, statins and proton pump inhibitors, and the presence of myocardial 
infarction, heart failure, peripheral vascular disease, cerebrovascular disease, connective tissue disease, 
dementia, chronic obstructive pulmonary disease, rheumatoid arthritis, diabetes, renal disease and liver disease.  
h Additionally adjusted for smoking, alcohol consumption and obesity using multiple imputation with chained 
equations with age, gender and deprivation used in the imputation, separately for cases and controls, using 
chained ordered logit models 




Appendix 1: List of generic and proprietary drug names for each exposure and confounder 
medication 
 
Substance Name Drug Name 
5AR Inhibitor Avodart, Dutasteride, Finasteride, Proscar 
Aspirin Asasantin, Aspirin, Caprin, Co-codaprin, Micropirin, Migramax, Nu-Seals 
Dutasteride Dutasteride, Avodart 
Finasteride Finasteride, Proscar 
Proton pump 
inhibitor 
Esomeprazole, Heliclear, Helimet, Lansoprazole, Losec, Nexium, Omeprazole, 
Pantoprazole, Pariet, Protium, Rabeprazole Sodium, Zoton 
Statin 
Atorvastatin, Cholib, Crestor, Dorisin, Fluvastatin, Inegy, Lescol, Lipitor, 
Lipostat, Luvinsta, Pinmactil, Pravastatin, Rosuvastatin, Simvador, 
Simvastatin, Stefluvin, Zocor 
  
